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Background: The role of n-3 polyunsaturated fatty acids (PUFA) in atrial fibrillation (AF) remains controversial. Little is known about their long term 
effects on atrial remodeling in chronic heart failure (CHF).
Methods: In this study, CHF was induced by intracoronary doxorubicin infusions. From a total of 20 sheep, there were: 6 PUFA treated CHF (CHF-
PUFA), 7 olive oil treated CHF (CHF-CTL) and 7 control (CTL) animals. Open chest electrophysiological study was performed with assessment of bi-
atrial effective refractory period (ERP) and conduction velocity. Cardiac function was monitored by magnetic resonance imaging. Tissue PUFA levels 
were quantified using chromatography.
Results: A 2-3 fold increase in atrial PUFA levels were seen in the CHF-PUFA group. PUFA prevented the development of CHF related left atrial 
enlargement but not left ventricular or atrial dysfunction. Atrial ERP was significantly lower in the CHF-PUFA group but ERP heterogeneity was 
unchanged. In addition, PUFA suppressed atrial conduction abnormalities seen in CHF of slowed/heterogeneous conduction and prolonged P wave 
duration. Duration of Induced AF episodes in CHF-PUFA was shorter although AF inducibility was unaltered.
Conclusions: In this ovine CHF study, chronic PUFA use protected against adverse atrial remodeling by preventing atrial enlargement and 
conduction abnormalities leading to shorter AF episodes despite lower ERP. The anti-arrhythmic effects of PUFA in CHF require further studies.
PUFA in Chronic Heart Failure
CTL
(n=7)
CHF-CTL
(n=7)
CHF-PUFA
(n=6)
P value
(ANOVA group effect)
Atrial EPA, %
Atrial DHA, %
2.9±0.6
2.1±0.2
3.5±0.5
1.8±0.5
9.1±1.4‡*
4.3±0.1‡*
<0.001
<0.001
LV EF, % 44±7 36±5† 35±6‡ 0.004
LA EDV, ml
LA ESV, ml
LA EF, %
29±7
19±2
32±2
40±2†
33±5†
25±5†
28±2*
21±2*
29±3
0.001
<0.001
0.008
P wave duration, ms 58±6 68±5† 61±1* 0.01
ERP (at 300ms)
RA, ms
LA, ms
171±34
136±19
184±40
155±35
134±21‡*
116±19‡*
<0.001
<0.001
Conduction velocity, m/s 0.90±0.16 0.75±0.09† 0.87±0.12* <0.001
Conduction heterogeneity index 1.20±0.33 1.37±0.35† 1.19±0.21* <0.001
AF inducibility, %
AF duration, s
3±3
2±4
22±28
20±23† 
5±5
1±1* 
0.2
0.02
Post-hoc comparisons with p<0.05: †CHF-CTL vs. CTL; ‡CHF-PUFA vs. CTL; *CHF-PUFA vs. CHF-CTL.
EPA, eicosapentaenoic acid; DHA, docosahexaenoic acid; LV, left ventricular; EF, ejection fraction; LA, left atrial; EDV, end-diastolic volume; ESV, 
end-systolic volume; RA, right atrial; ERP,effective refractory period; AF, atrial fibrillation.
